Endeavor BioMedicines to Present Quantitative Image Analysis from Phase 2a Trial of Taladegib (ENV-101) at European Respiratory Society (ERS) Congress 2026
Endeavor BioMedicines ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that results from a High-Resolution Computed Tomography (HRCT) post hoc analysis from its Phase 2a trial evaluating taladegib (ENV-101) in individuals with idiopathic pulmonary fibrosis (IPF) have been accepted as a late-breaking abstract for presentation at the European Respiratory Society (ERS) Congress 2026. The ERS Congress 2026 will take place from September 5 – 9 in Barcelona, Spain.
Following are details about Endeavor's presentation:
Title: Treatment with taladegib results in increased lung volume and regression of markers of ILD: A Phase 2a post hoc CT analysis using Brainomix e-Lung
Abstract ID: PA804
